Payment overview · 2025
General Payments
$1,169.60
60 reported records · 22 companies
Healthcare provider profile · identity verified
Jennifer Earsing, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · NIAGARA FALLS, NY · NPI 1699054742
Verified facts
What the public records show
CMS Open Payments records show Jennifer Earsing, NP received $1,169.60 in general payments during 2025 across 60 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 12.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.54 | 12.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.80 | 10.0% | 9 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $85.17 | 7.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.63 | 6.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.60 | 6.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.75 | 5.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.86 | 5.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.55 | 4.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.64 | 4.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.82 | 4.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.61 | 4.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.17 | 4.3% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $43.69 | 3.7% | 2 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $42.53 | 3.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.22 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.30 | 2.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $28.08 | 2.4% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $25.16 | 2.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.04 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.43 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.13 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.88 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,169.60 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $145.54 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $97.99 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $85.17 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.38 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.75 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.64 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $50.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.61 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $50.17 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $43.69 | 2 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.20 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.94 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $28.08 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 144 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
62 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
144 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 629 | 170 |
| Lisinopril | Lisinopril | 514 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 111 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 61 |
| Alprazolam | Alprazolam | 239 | 42 |
| Metformin Hcl | Metformin Hcl | 226 | 58 |
| Gabapentin | Gabapentin | 217 | 47 |
| Omeprazole | Omeprazole | 216 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 34 |
| Mounjaro | Tirzepatide | 144 | 26 |
| Montelukast Sodium | Montelukast Sodium | 126 | 28 |
| Furosemide | Furosemide | 125 | 37 |
| Sertraline Hcl | Sertraline Hcl | 122 | 28 |
| Valsartan | Valsartan | 111 | 21 |
| Trazodone Hcl | Trazodone Hcl | 110 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 17 |
| Celecoxib | Celecoxib | 104 | 18 |
| Losartan Potassium | Losartan Potassium | 102 | 34 |
| Ibuprofen | Ibuprofen | 101 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 25 |
| Eliquis | Apixaban | 96 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 21 |
| Jardiance | Empagliflozin | 93 | 21 |
| Tramadol Hcl | Tramadol Hcl | 90 | 17 |
| Carvedilol | Carvedilol | 89 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 26 |
| Allopurinol | Allopurinol | 85 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 24 |
| Famotidine | Famotidine | 79 | 20 |
| Spironolactone | Spironolactone | 74 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 14 |
| Potassium Chloride | Potassium Chloride | 73 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 16 |
| Simvastatin | Simvastatin | 70 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 19 |
| Clonazepam | Clonazepam | 67 | 13 |
| Trulicity | Dulaglutide | 66 | 11 |
| Atenolol | Atenolol | 65 | 20 |
| Prednisone | Prednisone | 64 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 19 |
| Myrbetriq | Mirabegron | 62 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 13 |
| Pregabalin | Pregabalin | 55 | 12 |
| Ramipril | Ramipril | 52 | 15 |
| Glipizide | Glipizide | 51 | 19 |
| Repatha Sureclick | Evolocumab | 49 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | 12 |
| Diazepam | Diazepam | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | 13 |
| Xarelto | Rivaroxaban | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Baclofen | Baclofen | 41 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Azithromycin | Azithromycin | 38 | 37 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 13 |
| Ozempic | Semaglutide | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | 11 |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Nystatin | Nystatin | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tegretol Xr | Carbamazepine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Veozah | Fezolinetant | 14 | suppressed |
| Aplenzin | Bupropion Hbr | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Clonidine | Clonidine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Unifine Pentips Plus | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Epinephrine | Epinephrine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,169.60 · 60 records | Bayer Healthcare Pharmaceuticals Inc. | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FEMLYV, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, MYFEMBREE, NEXPLANON, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, WATCHMAN FLX, Wegovy, YUPELRI, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error